ScandiDos has recruited Gustaf Piehl as new CEO
Gustaf Piehl will replace Görgen Nilsson as Managing Director of ScandiDos AB on September 7. Gustaf has many years of experience in the radiation therapy industry after holding a number of different roles within the Elekta Group over the past 17 years. He has most recently been responsible for Elekta's acquisition activities, but previously held operational roles in, among others, Elekta's sales & marketing company in India and was CEO of Global Medical Investments, GMI AB.
- We are very pleased to have been able to attract Gustaf to ScandiDos and we look forward to the expertise he brings to ScandiDos. Gustaf has a very broad experience from his time at Elekta, one of the truly innovative companies in radiation therapy, and brings a wide range of knowledge that will be very valuable to ScandiDos’ future development, says Chairman Olof Sandén.
- I really look forward to joining the highly competent team at ScandiDos to jointly take the next step in the company's commercial development. The needs and complexity of quality assurance of modern radiotherapy have increased significantly in recent years and ScandiDos is well positioned to assist users in meeting these growing needs”, says Gustaf Piehl.
For further information
Olof Sandén, Chairman of ScandiDos, tel. 076 2008258, email@example.com
With its product Delta4 Phantom+, ScandiDos has taken a leading role in advanced dosimetry and quality assurance of modern radiation therapy of cancer. With the product Delta4 Phantom+ MR, ScandiDos has expanded the role to also apply to the new area of MR-controlled radiation therapy. The Delta4 Discover product is ScandiDos’ disruptive innovation that uniquely enables independent radiation dose verification during treatment, which is the future way to perform quality assurance in radiation therapy of cancer. ScandiDos’ measurement system and advanced calculation programs give doctors, physicists and patients a receipt that the advanced and complicated treatment can be delivered and is delivered as prescribed.
The head office is located in Uppsala Science Park, where product development is carried out. Sales are carried out by sales offices in the USA, Malaysia and France, directly in the Nordic countries and through distributors in over 45 countries. ScandiDos has collaborations with the two largest therapy companies Varian and Elekta.
ScandiDos has been listed on NASDAQ First North Stockholm since April 2014 under the code SDOS. Erik Penser Bank, www.penser.se, is hired as a Certified Adviser.